Cibus (CBUS) Share-based Compensation (2016 - 2025)
Cibus (CBUS) posted Share-based Compensation of -$6.2 million for Q4 2025, down 198.37% sequentially from $6.3 million in Q3 2025, and down 328.71% YoY from $2.7 million in Q4 2024.
Cibus (CBUS) Share-based Compensation (2016 - 2025) Analysis & Trends
Cibus has reported Share-based Compensation for 10 years, with the latest figure at -$6.2 million in Q4 2025.
- Quarterly Share-based Compensation fell 328.71% year-over-year to -$6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $142000.0 (down 98.68% YoY) and the FY2025 annual result came in at $142000.0, down 98.68% from the prior year.
- Share-based Compensation retreated to -$6.2 million in Q4 2025 per CBUS's latest filing, from $6.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $10.9 million in Q3 2023 and troughed at -$6.2 million in Q4 2025.
- A 5-year average of $1.7 million and a median of $1.2 million in 2021 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 1867.72% in 2025, down 2927.59% in 2025.
- Over 5 years, Share-based Compensation stood at $1.2 million in 2021, then surged by 226.37% to $4.0 million in 2022, then advanced by 10.61% to $4.4 million in 2023, then tumbled by 38.49% to $2.7 million in 2024, then slumped by 328.71% to -$6.2 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered -$6.2 million, $6.3 million, and -$2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | - |
| 10 | Cibus | 131.25 Mn | 110.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.22 Mn |
| Dec 31, 2025 | -6.22 Mn |
| Sep 30, 2025 | 6.32 Mn |
| Sep 30, 2025 | 6.32 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | 2.50 Mn |
| Mar 31, 2025 | 2.50 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Sep 30, 2024 | 7.82 Mn |
| Sep 30, 2024 | 7.82 Mn |
| Jun 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 127,000.00 |
| Mar 31, 2024 | 127,000.00 |
| Dec 31, 2023 | 4.42 Mn |
| Dec 31, 2023 | 4.42 Mn |
| Sep 30, 2023 | 10.93 Mn |
| Sep 30, 2023 | 10.93 Mn |